A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors.
Gan HK, Mitchell PL, Galettis P, Davis ID, Cebon J, de Souza P, Links M. Department of Medical Oncology and Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Melbourne, VIC, Australia. huikg@bigpond.net.au

Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.
Porta C, Zimatore M, Bonomi L, Imarisio I, Paglino C, Sartore-Bianchi A, Mutti L. Medical Oncology, I.R.C.C.S. San Matteo University Hospital, Piazzale C. Golgi, I-27100 Pavia, Italy. c.porta@smatteo.pv.it

Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma.
Fennell DA, C Steele JP, Shamash J, Sheaff MT, Evans MT, Goonewardene TI, Nystrom ML, Gower NH, Rudd RM. Lung and Mesothelioma Unit, Department of Medical Oncology, St Bartholomew's Hospital, West Smithfield, London EC1A 7BE, United Kingdom. d.a.fennell@qmul.ac.uk

A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma.
Schutte W, Blankenburg T, Lauerwald K, Schreiber J, Bork I, Wollscgkaeger B, Treutler D, Schneider CP, Bonner R. Second Medical Department, City hospital Martha-Maria Halle-Doelau, Halle, Germany. wolfgang.schuette@medizin.uni-halle.de

Oxaliplatin and raltitrexed in the treatment of inoperable malignant pleural mesothelioma: results of a pilot study.
Maisano R, Caristi N, Toscano G, Aragona M, Spadaro P, Amadio P, Mare M, Zavettieri M, La Torre F. IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Messina, Italy. maisano@supereva.it